Scarica l'app Stockscreener
13.57
5.76%
-0.83
Dopo l'orario di chiusura:
13.58
0.010
+0.07%
Precedente Chiudi:
$14.40
Aprire:
$14.65
Volume 24 ore:
1.33M
Relative Volume:
2.05
Capitalizzazione di mercato:
$686.96M
Reddito:
$89.04M
Utile/perdita netta:
$-241.08M
Rapporto P/E:
-2.5798
EPS:
-5.26
Flusso di cassa netto:
$-194.72M
1 W Prestazione:
-4.17%
1M Prestazione:
+11.14%
6M Prestazione:
+57.42%
1 anno Prestazione:
+72.65%
Intervallo 1D:
$12.91
$14.65
Intervallo di 1 settimana:
$12.91
$14.65
Portata 52W:
$5.035
$15.41
Regenxbio Inc Stock (RGNX) Company Profile
Nome
Regenxbio Inc
Settore
Industria
Telefono
240-552-8181
Indirizzo
9804 MEDICAL CENTER DRIVE, ROCKVILLE, MD
Confronta RGNX con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
RGNX
Regenxbio Inc
|
13.57 | 728.97M | 89.04M | -241.08M | -194.72M | -5.26 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.13 | 115.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
776.31 | 81.12B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
400.17 | 52.54B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
839.99 | 51.78B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
177.12 | 37.12B | 447.02M | -1.18B | -906.14M | -6.1812 |
Regenxbio Inc Stock (RGNX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-02-11 | Downgrade | Goldman | Buy → Neutral |
| 2025-02-07 | Ripresa | Raymond James | Outperform |
| 2024-11-15 | Ripresa | Morgan Stanley | Overweight |
| 2024-10-10 | Ripresa | Raymond James | Outperform |
| 2024-06-07 | Iniziato | Goldman | Buy |
| 2024-03-11 | Iniziato | H.C. Wainwright | Buy |
| 2024-03-08 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2024-03-06 | Aggiornamento | Leerink Partners | Market Perform → Outperform |
| 2024-02-21 | Ripresa | Raymond James | Outperform |
| 2023-11-01 | Iniziato | Stifel | Buy |
| 2023-06-02 | Iniziato | Robert W. Baird | Outperform |
| 2022-06-23 | Iniziato | Berenberg | Buy |
| 2021-12-15 | Iniziato | Wedbush | Neutral |
| 2021-10-19 | Ripresa | Morgan Stanley | Overweight |
| 2021-01-06 | Aggiornamento | Raymond James | Outperform → Strong Buy |
| 2020-12-16 | Iniziato | UBS | Buy |
| 2020-06-25 | Ripresa | BofA/Merrill | Buy |
| 2020-05-13 | Iniziato | RBC Capital Mkts | Sector Perform |
| 2019-08-20 | Aggiornamento | SVB Leerink | Underperform → Mkt Perform |
| 2019-06-18 | Reiterato | Chardan Capital Markets | Buy |
| 2019-06-14 | Ripresa | Raymond James | Outperform |
| 2019-06-05 | Reiterato | Chardan Capital Markets | Buy |
| 2019-02-25 | Aggiornamento | Evercore ISI | In-line → Outperform |
| 2019-02-05 | Aggiornamento | Raymond James | Outperform → Strong Buy |
| 2018-12-17 | Reiterato | Chardan Capital Markets | Buy |
| 2018-11-08 | Reiterato | BofA/Merrill | Neutral |
| 2018-08-08 | Reiterato | Chardan Capital Markets | Buy |
| 2018-07-23 | Downgrade | BofA/Merrill | Buy → Neutral |
| 2018-07-10 | Reiterato | Chardan Capital Markets | Buy |
| 2018-05-09 | Reiterato | Barclays | Overweight |
| 2018-04-09 | Reiterato | Chardan Capital Markets | Buy |
| 2018-03-12 | Downgrade | Evercore ISI | Outperform → In-line |
| 2018-02-13 | Iniziato | Mizuho | Neutral |
| 2017-11-09 | Ripresa | Morgan Stanley | Overweight |
Mostra tutto
Regenxbio Inc Borsa (RGNX) Ultime notizie
REGENXBIO updates Phase 1/2 data for Duchenne candidate - MSN
Trading the Move, Not the Narrative: (RGNX) Edition - Stock Traders Daily
Prospects for Regenxbio’s clemidsogene lanparvovec approval in Hunter syndrome - The Pharma Letter
REGENXBIO (NASDAQ:RGNX) Trading Down 3.8%Here's Why - MarketBeat
REGENXBIO Inc. (NASDAQ:RGNX) Surges 27% Yet Its Low P/S Is No Reason For Excitement - simplywall.st
Behavioral Patterns of RGNX and Institutional Flows - Stock Traders Daily
REGENXBIO (NASDAQ:RGNX) Hits New 1-Year HighWhat's Next? - MarketBeat
Assenagon Asset Management S.A. Purchases 132,942 Shares of REGENXBIO Inc. $RGNX - MarketBeat
REGENXBIO Inc. (NASDAQ:RGNX) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
Stifel raises Regenxbio stock price target to $45 on upcoming catalysts By Investing.com - Investing.com Australia
Stifel Maintains REGENXBIO (RGNX) Buy Recommendation - Nasdaq
REGENXBIO (NASDAQ:RGNX) Shares Up 9.2%What's Next? - MarketBeat
What hedge fund activity signals for REGENXBIO Inc. stockCPI Data & Breakout Confirmation Trade Signals - DonanımHaber
Stifel Raises Price Target for Regenxbio (RGNX) to $45 | RGNX St - GuruFocus
Stifel raises Regenxbio stock price target to $45 on upcoming catalysts - Investing.com Nigeria
Decliners Report: How interest rate cuts could boost REGENXBIO Inc. stockQuarterly Profit Review & Risk Adjusted Buy/Sell Alerts - Улправда
Why REGENXBIO Inc. stock is recommended by analystsTreasury Yields & Detailed Earnings Play Alerts - DonanımHaber
Squarepoint Ops LLC Boosts Holdings in REGENXBIO Inc. $RGNX - MarketBeat
Will REGENXBIO Inc. stock reach Wall Street targetsForecast Cut & Daily Profit Focused Stock Screening - DonanımHaber
Is REGENXBIO Inc. stock a smart buy before Fed meetingJuly 2025 Trends & Scalable Portfolio Growth Ideas - ulpravda.ru
How interest rate cuts could boost REGENXBIO Inc. stockPortfolio Gains Report & Consistent Return Investment Signals - Улправда
Is REGENXBIO Inc. stock a contrarian buy2025 Risk Factors & Fast Entry Momentum Trade Alerts - Улправда
REGENXBIO to Present at the 44th Annual J.P. Morgan Healthcare Conference - The AI Journal
Leerink Partners Maintains REGENXBIO (RGNX) Outperform Recommendation - Nasdaq
Leerink Partners raises Regenxbio stock price target to $20 on DMD opportunity By Investing.com - Investing.com South Africa
Regenxbio (RGNX): Leerink Partners Raises Price Target to USD 20 - GuruFocus
Leerink Partners raises Regenxbio stock price target to $20 on DMD opportunity - Investing.com Nigeria
REGENXBIO (NASDAQ:RGNX) Reaches New 1-Year HighWhat's Next? - MarketBeat
RegenXBio’s gene therapy study for Hunter syndrome: A potential game-changer - MSN
RegenXBio’s Gene Therapy Study for Hunter Syndrome: A Potential Game-Changer - TipRanks
REGENXBIO (NASDAQ:RGNX) Stock Price Up 5.2%Time to Buy? - MarketBeat
(RGNX) Movement Within Algorithmic Entry Frameworks - news.stocktradersdaily.com
REGENXBIO (NASDAQ:RGNX) Reaches New 52-Week HighShould You Buy? - MarketBeat
Wet Age-Related Macular Degeneration Market Growth - openPR.com
Voss Capital LP Boosts Stock Holdings in REGENXBIO Inc. $RGNX - MarketBeat
REGENXBIO Inc. $RGNX is 22NW LP's 5th Largest Position - MarketBeat
Regenxbio Stock Jump Looks Great, But How Secure Is That Gain? - Trefis
Will REGENXBIO Inc. (RB0) stock announce special dividend2025 Major Catalysts & Real-Time Volume Spike Alerts - Newser
What insider trading reveals about REGENXBIO Inc. stockJuly 2025 Snapshot & Smart Allocation Stock Tips - Newser
Why global investors buy REGENXBIO Inc. (RB0) stock2025 Market WrapUp & Safe Capital Allocation Plans - Newser
Will REGENXBIO Inc. (RB0) stock profit from fiscal stimulus2025 Big Picture & Safe Entry Zone Identification - Newser
Can REGENXBIO Inc. stock resist market sell offsQuarterly Profit Review & Technical Pattern Based Signals - Newser
Is REGENXBIO Inc. stock resilient to inflationGold Moves & Fast Exit Strategy with Risk Control - Newser
JPMorgan Chase & Co. Sells 512,318 Shares of REGENXBIO Inc. $RGNX - MarketBeat
Will REGENXBIO Inc. (RB0) stock see valuation expansionWeekly Trade Analysis & Reliable Trade Execution Plans - Newser
Regenxbio Inc Azioni (RGNX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.57%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):